chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This is a non serious spontaneous case from a consumer in the USA who experienced postnasal drip after receiving FluMist. The reporter causality is not provided. A 49 year old female experienced post-nasal drip, nasal congestion, muscle pain and abdominal pain on day after receiving FluMist on 01/04/05. The patient received the FluMist at a doctor's office where she works. The patient reported that the nurse administering the vaccines accidentally left them in the office at room temperature from the afternoon of 01/05/03, but initially thought that they can still use them. It was after 01/05/05, the patient experienced abdominal pain, which was relieved spontaneously without any intervention. She also reported post-nasal drip, nasal congestion and muscle pains for which she took Tylenol and Allegra together with herbal echinacea. The patient stated that the symptoms have since lessened. The patient has not yet recovered.
Still dizzy/lightheaded; Unsteady; He felt the room was spinning; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. An 85-year-old male patient received BNT162b2 (BNT162B2), on 08Apr2022 at 12:00 as dose 4 (booster), single (Lot number: FJ9441) at the age of 85 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, Single, Lot Number: EK4176, Location of injection: Arm Left, Vaccine Administration Time: 04:30 PM), administration date: 11Jan2021, when the patient was 84-year-old, for Covid-19 immunization, reaction(s): "None"; BNT162b2 (Dose 2, Single, Lot Number: EC3247, Location of injection: Arm Right, Vaccine Administration Time: 03:00 PM), administration date: 01Feb2021, when the patient was 84-year-old, for Covid-19 immunization, reaction(s): "None"; BNT162b2 (Dose 3, Single, Lot Number: FO3448, Location of injection: Arm Left, Vaccine Administration Time: 02:00 AM), administration date: 28Aug2021, when the patient was 85-year-old, for Covid-19 immunization, reaction(s): "None". The following information was reported: VERTIGO (non-serious) with onset 10Apr2022, outcome "not recovered", described as "He felt the room was spinning"; BALANCE DISORDER (non-serious) with onset 11Apr2022, outcome "not recovered", described as "Unsteady"; DIZZINESS (non-serious) with onset 12Apr2022, outcome "not recovered", described as "Still dizzy/lightheaded". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of vertigo, balance disorder, dizziness.  Additional information: Facility type vaccine was pharmacy or drug store. No other vaccine in four weeks. No known allergies. No other medical history.  No follow-up attempts are possible. No further information is expected.
Initial unsolicited report received from a nurse via partner company Pfizer (manufacturer reference Number: 2017126010) on 06-APR-2017. This case involves a patient (onset age and gender were unknown) who was vaccinated with dose of TETANUS TOXOID (TETANUS VACCINE) (batch number, expiry date, dose and dose in series were not reported) in an unknown site on an unknown date. Patient's medical history and concomitant medications were not reported. On an unknown date, following the vaccination, the patient had experienced a reaction to a tetanus vaccine. Laboratory investigations and corrective treatment were not reported. The outcome of the event was not reported. List of documents held by sender: none.
Patient received moderna vaccine on 3/4/21 and 4/1/21. Presented to ER on 6/14/22 and found to be covid positive incidentally. Admitted for multiple sclerosis exacerbation. No symptoms of COVID19. Discharged on 6/20/22
pre existing condition; peripheral neuropathy; and it has got a little worse; neuropathy was aggravated; This is a spontaneous report from a contactable consumer (patient) via Pfizer-sponsored program COVAX US support.  A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot number: not reported), via an unspecified route of administration on 02Aug2021 as dose 1, single for COVID-19 immunization. Medical history included peripheral neuropathy (Now he has a pre-existing condition which is Peripheral Neuropathy (Medical Condition)). Concomitant medications were not reported. On an unspecified date in Aug2021, the patient experienced pre-existing condition; peripheral neuropathy; and it has got a little worse; neuropathy was aggravated. The outcome of the event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
This spontaneous report was received from a 79 year old male consumer (reporting on himself). The patient did not have a pertinent medical history or drug reaction allergies. In November 2007 the patient was vaccinated with a dose of ZOSTAVAX (Lot #, dose and route not reported). There was no concomitant therapy. In August 2012, the patient was diagnosed with shingles and since this same date, the patient had suffered with postherpetic neuralgia (PHN). The patient was prescribed revaccination of the ZOSTAVAX vaccine two months ago by his physician and as a result of receiving literature from the pharmacy, advising him to get revaccinated, even though he was still experiencing PHN, to prevent a second outbreak of shingles. The patient stated his PHN has gotten worse covering an area from the left side of trunk of chest around under his left arm to the middle of his back to the spine. The patient sought medical attention and was prescribed with LYRICA. Laboratory diagnostic studies were not performed. At the time of the report the patient's outcome was not recovered.  Additional information has been requested.
Reported swelling and redness at injection site starting around 12:30 PM.  At 13:30 PM had a near-syncopal episode with slurred speech; remembers feeling hot and dizzy just prior to syncope.  Seen in ER; received IV Famotidine, Solu-Medrol, and Benadryl.  No airway compromise, no hives.
he had a severe case of diarrhea that lasted 6 weeks; headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) and DIARRHOEA (he had a severe case of diarrhea that lasted 6 weeks) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025L20A and 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Feb-2021, the patient experienced HEADACHE (headache) and DIARRHOEA (he had a severe case of diarrhea that lasted 6 weeks). At the time of the report, HEADACHE (headache) and DIARRHOEA (he had a severe case of diarrhea that lasted 6 weeks) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications provided. Patient  consulted with his primary care provider who prescribed him some medications. No specific medications reported.   This case was linked to US-MODERNATX, INC.-MOD-2021-114763 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-114763:
patient came into the ed for bilateral eye swelling that started Monday night two days after vaccination - treated for allergic rxn Benadryl solumedrol Pepcid
Dizziness, lightheaded, cold, vision trouble. 911 called. Vitals checked, stable. Sat for 30min, refused emergency room. Went home with parents.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. Patient's pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/allergies were reported. On 10-JUN-2016, the patient was vaccinated with improperly stored dose of ROTATEQ (lot # L035276 and expiration date 09-JUN-2017) (strength, dosing details and anatomical location were not reported). No adverse effects were reported. No product quality complaint was involved. This is one of several reports received by the same reporter. Additional information has been requested.
febrile szs 20JAN96 2AM;20JAN96 T101 @ 11PM 19JAN96; found bilat OM & blood culture sowed strep;rash appeared 23JAN96
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 43-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Sep2022 at 13:00 as dose 5 (booster), single (Lot number: GH9702) at the age of 43 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Lymphoma" (unspecified if ongoing); "in remission" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19.
ARM WAS EXTREMELY SWOLLEN AND PAINFUL THE DAY ON INJECTION 09/09/20. THE FOLLOWING DAY 09/10/20 SORENESS AND REDNESS SEVERE AND SWELLING AND REDNESS AND HEAT STARTED. I APPLIED ICE PACK. ON THE FOLLOWING DAY, FRIDAY I CALLED THE CLINIC, MY DOCTOR WAS OFF. I WAS DIRECTED TO THE NURSE LINE WHO SENT NOTE TO MY CLINIC. I WAS CALLED AND CLINIC NURSE STATED THE I WOULD BE GETTING A CALL VIRTUAL APPOINTMENT WITH THE NURSE PRACTITIONER. I WAS ASSESSED AND INSTRUCTED TO APPLY ICE PACK, PLACED ON  PREDNISONE 20 MG 2 TABS/DAY FOR 3 DAYS. APPLY ICE PACKS AS NEEDED, TO REPORT TO URGENT CARE IF WORSENS.
Rash on right forearm, small blisters on right shoulder (area the size of a 1/2 dollar), tingling in her right shoulder. Pt reported this to us on 11/25/2016 at 12:13. She then went to urgent care and was diagnosed with having shingles. Pt was given a 7 day course of valacyclovir.
On morning of 27th, woke up with swollen, red left kneecap. I couldn't walk on it. It was red all around the knee. Went to Urgent Care - diagnosed it as cellulitis - gave me antibiotics for it. Went back to Urgent care the next day - on the 28th - because the redness had spread quite a bit and they upped the dose of antibiotics. The first two days, I couldn't put weight on it but then it started to slowly improve. It began to resolve - it took for four or five days for it to resolved completely.
Arm hurts; Arm feels numb; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm hurts) and HYPOAESTHESIA (Arm feels numb) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049L21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Johnson & Johnson (1st Dose). Past adverse reactions to the above products included No adverse event with Johnson & Johnson.    On 02-May-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-May-2022, the patient experienced PAIN IN EXTREMITY (Arm hurts) and HYPOAESTHESIA (Arm feels numb). The patient was treated with IBUPROFEN for Pain in arm and Numbness of upper arm, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Arm hurts) outcome was unknown and HYPOAESTHESIA (Arm feels numb) had not resolved.            No concomitant medication was provided.  Patient received the first booster of the Moderna COVID 19 vaccine on 02-May-2022.   Patient took Ibuprofen as treatment, but patient arm was still feeling numb.   This case was linked to MOD-2022-557662 (Patient Link).
Dose 1:  Facial swelling, tongue tingling. Dose 2:  Approx. 4 weeks after second dose: moderate to severe glossodynia symptoms on tongue, gums, lips, palate, throat; aching tonsillar lymph nodes; paresthesias along trigeminal nerve left side of face; papillae peeling on tongue. periodic rash on arms, periodic nausea. These symptoms were constant and daily, and severe, through the months of May, June and July, and began lessening in to become mild symptoms throughout August. Symptoms still present on this date but very gradually subsiding.
I had an extreme headache, fatigue, slight cough, sneezing, felt feverish. I tested positive for COVID-19 and was prescribed Paxlovid. When I was taking Paxlovid my face was very flush and my ears were red, they also burned a little.
It was reported that a pt (3 of 3) experienced a local reaction sometime after receiving a combination vaccine of Tripedia and ActHIB given as TriHIBit. No specifics were provided.
Same as reported in 03/22/2021 report, itchy rash. Still experiencing itchy rash.
The vaccine storage did not meet standards, vaccine stored in freezer beyond allowable time. Recommend revaccination.
itching, skin was hot and red with welts on both arms would come and go throughout the day lasting 3 days. Went to see PCP recommended antihistamine for treatment.
Patient reported ongoing pain in left arm (limited movement/strength) since vaccination. Patient has not sought treatment.
Reconstitution with unknown diluent; did not use the supplied CYW-135 liquid conjugate portion to reconstitute the dose; This case was reported by a nurse via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMXA721A, expiry date 30th September 2023) for prophylaxis.   Previously administered products included Menveo (received first dose on 16th November 2018).   On 3rd January 2023, the patient received the 2nd dose of Menveo. On 3rd January 2023, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK receipt date: 5-Jan-2023 Reporter's comment: The nurse reported that a colleague administered a dose of Menveo to a patient, however the nurse did not use the supplied CYW-135 liquid conjugate portion to reconstitute the dose.   The nurse that administered the vaccine was not in the office on the day of reporting, so it was unknown what diluent was used for reconstitution.   At the time of reporting, the dose had not been repeated. The vaccine administration facility was the same as primary reporter. The reporter gave permission for follow-up. Additional supportive information: The patient received a dose of Menveo with unknown diluent, however the nurse did not use the supplied CYW-135 liquid conjugate portion to reconstitute the dose, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered.
Started out with rash on my upper back , severe fatigue, then joint swelling in fingers of both hands. Same thing happened after booster but no rash.
Cardiac arrhythmia, tingling in head, brain fog, dysautonomia, light sensitivity, tachycardia with any exertion.
This spontaneous report as received from a physician via company representative refers to a 16 year old female patient. On an unknown date in 2014 (reported as within the last two weeks) the patient was inadvertently administered ZOSTAVAX instead of (Oka/Merck) VARIVAX (dose, route, anatomical location, lot number and expiration date were unspecified). No adverse effects reported. No concomitant therapies were reported. The outcome of event was unknown. Additional information has been requested.
Information has been received from a pharmacist referring to a 20 years old female patient. The patient's concurrent condition, medical history, and concomitant medication were not provided. On 22-Aug-2016, the patient was vaccinated with a dose of (Oka/Merck) VARIVAX (dose, route, lot number and expiration date were unknown. In August 2016 (reported as after the (Oka/Merck) VARIVAX was administered), the patient experienced grossly swollen tonsils and sore throat. The patient saw her unspecified healthcare provider on 01-SEP-2016 for the events to seek medical attention. The patient was prescribed prednisone (unspecified dose) as treatment for 5 days. The events was not resolved until 01-SEP-2016. The causal relationship between the events and (Oka/Merck) VARIVAX was unknown. Additional information has been requested.
New onset Nephrotic syndrome with onset of urine foaming and edema that began after the vaccination.  exact timing not clear but pt does not feel that he had these complaints prior to receiving the vaccine.  He required hospitalization in a county Hospital on 8/12/21. for his nephrotic syndrome and acute kidney injury, and has 6 gm of total urine protein, albumin 1.2.  He also has crohns that's been stable but has had weight loss, anorexia and more diarrhea over the prior 2 weeks, though GI consult does not feel that it is due to a flare of Crohns.  A Renal Biopsy is pending
The night of vaccine administration, patient reported fever, chills, and confusion that worsened as the day progressed. He also reported decreased appetite, weakness, and shivering. In addition, he became disoriented and incoherent, prompting his wife to call EMS who took him to the ED. While in the ED, he was diagnoses with systemic inflammatory response syndrome (SIRS), with no sources of infection found. He was also found to be in AKI likely prerenal secondary to dehydration and diuretic/ARB use.
A 70 year old female consumer reported that she received Pnu-Imune 23 vaccine in March, 2002. Concomitant medication included Prempro. Medical history includes Fuchs' Dystrophy of the eyes. Two weeks, post vax, she developed an injection site reaction characterized by redness, heat and swelling. She stated that this also occurred 8 years ago following receipt of a pneumococcal vaccine (mfr unk). See case HQ1576603APR2002. No additional information was available as of the date of this report.
Less than 24 hours after receiving the vaccine (Jan 7), I started experiencing bad stomach pain, which a family friend had also experienced after she received the vaccine (also ~24 hours later). It did not subside with time, and became feeling like a shooting pain that was coming and going in waves, and I could not sleep that night. I was nauseous at one point, and threw up. I drank water throughout the night, which seemed to help a little bit and was taking an NSAID. The following day (Jan 8), the shooting pain continued, and I was in bed all day. I became nauseous at one point during the day, when attempting to move a piece of furniture, but did not throw up. I continued taking NSAIDs, which did not help. I was able to sleep through the night after taking melatonin, but was in discomfort. The following day (Jan 9), I woke up, and the shooting stomach pain had radiated to my chest, and had not subsided. I called my PCP, who I was unable to see due to timing/distance from the office, and she recommended I go to an ED if I did not feel better. As the pain was in my chest, and I wasn't sure if it had radiated there or was cardiac related, I had a friend drive me to the ED. My results came back normal at the ED, and the PA was only able to tell me that it was GI related, due to the pain in my stomach/esophagus. She was unsure if it's GERD, gas trapped, or some other GI issue. I am still experiencing this pain (Jan 11), but have somewhat managed it by taking Tums and eating alkaline foods.
This spontaneous report was received from a pharmacist, referring to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 20-OCT-2015, the patient was vaccinated with an improperly stored dose of RECOMIBIVAX HB (Lot# L016427; expiration date: 13-APR-2017) (dose and route of administration were not provided). Concomitant therapies were not reported. No adverse effects reported. The pharmacist explained that the RECOMBIVAX HB doses were not involved in a previous temperature excursion and this time the temperature and time frame were: 1.4C for 22 hours 52 minutes and 8.6C for 112 hours 5 minutes. This is one of several reports from the same source (original report 1602USA004808). Additional information has been requested.
Patient stated the night after her injection her arm was extremely sore, she had difficulty sleeping.  For a few days after the shot, patient took ibuprofen 2 tablets three or four times daily.  Since then she always has a "dull ache" in her shoulder.  She has pain when trying to complete normal daily activities, such as sleeping on her left side, curling her hair and turning the steering wheel.   Patient presented to pharmacy the evening of 10/26/2020 - pharmacist examined patient shoulder.  Patient stated she was given the shot too high in her opinion.  Pharmacist tried to examine deltoid for where the shot was given, and could not identify it.  Arm and shoulder were normal color and did not appear swollen.   Instructed patient to use an ice pack, and continue with OTC NSAIDS for a few more days.
Says a relative had severe nose bleeds and headaches from the vaccine; Says a relative had severe nose bleeds and headaches from the vaccine; This is a spontaneous report received from a non-contactable consumer via Pfizer sponsored Program Support. A patient of unspecified age and gender received bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: was not reported), via an unspecified route of administration on an unspecified date as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient had experienced severe nose bleeds and headaches from the vaccine. At the time of reporting the outcome of the events was unknown. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt developed a red area about 80mm X 40mm on leg, that was warm to touch and slightly tender to touch. Site of problem area Rt leg.
I noticed tenderness around my shoulder where injection was made.  Last night (12/30) at home I noticed when I was laying down that on my left collar bone felt very tender and swollen.  I had my spouse feel both left and right collar bones and said that it is very swollen and looked as to if I broke my collar bone.  I came into work and showed and advised my manager and she advised me to contact you all with my side effect.
periods of high blood pressure; This spontaneous case was reported by a consumer and describes the occurrence of HYPERTENSION (periods of high blood pressure) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERTENSION (periods of high blood pressure). At the time of the report, HYPERTENSION (periods of high blood pressure) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: high (High) high.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided.  No treatment medications were provided.